Brief: Celyad Oncology To Sell Up to $25 Mln Of New American Depositary Shares
14/09/2020 07:12
Sept 14 (Reuters) - Celyad Oncology CYAD.BR :
* CELYAD ONCOLOGY ESTABLISHES AT-THE-MARKET FACILITY
* TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN OPEN MARKET SALE
* CURRENTLY INTENDS TO USE NET PROCEEDS FROM SALES OF ADSS IN ATM FOR
GENERAL
CORPORATE PURPOSES, INCLUDING BUT NOT LIMITED TO RESEARCH AND DEVELOPMENT OF
COMPANY’S CLINICAL AND PRECLINICAL CAR T CELL THERAPY CANDIDATES
* SALES OF ADSS IN ATM WILL ONLY BE CONDUCTED IN UNITED STATES THROUGH
NASDAQ
STOCK MARKET OR ANY OTHER EXISTING U.S. TRADING MARKET FOR ADSS
* NO SALES OF ADSS WILL BE CONDUCTED IN BELGIUM OR THROUGH EURONEXT
* MAY FROM TIME TO TIME SELL, FOR A PERIOD OF UP TO 36 MONTHS, THROUGH ATM,
WITH
JEFFERIES ACTING AS SALES AGENT, UP TO $25,000,000 OF NEW AMERICAN DEPOSITARY
SHARES ("ADSS")
* ACTUAL NUMBER OF ADSS ISSUED WILL VARY DEPENDING ON SALES PRICES UNDER
THIS
OFFERING, HOWEVER NUMBER OF ORDINARY SHARES SHALL NOT EXCEED 2,777,777 SHARES
* NEW ADSS WILL BE SOLD AT THEN CURRENT MARKET PRICES
Source text for Eikon: ID:nBwbvbcL1a
Further company coverage: CYAD.BR
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))